Sanofi's Leadership Shocker: Hudson's Exit Signals Strategic Recalibration

The pharmaceutical industry witnessed a significant executive shocker this week as Sanofi SA (NASDAQ: SNY) announced the departure of Chief Executive Officer Paul Hudson after six years at the helm. The Board of Directors made the decision not to renew Hudson’s mandate, with February 17, 2026, marking his final day as CEO. This abrupt transition reflects mounting investor pressure and the company’s struggle to navigate evolving market dynamics.

The Leadership Transition: A Calculated Move

Belén Garijo will assume the role of Chief Executive Officer, officially taking over at the conclusion of Sanofi’s Annual General Meeting on April 29, 2026. During the interim period, Olivier Charmeil, Executive Vice President of General Medicines, will serve as acting leader. Garijo arrives with considerable credentials—she previously led Merck KGaA from 2021 onward, making history as the first woman to head a DAX40 company in Germany.

The Board emphasized that Garijo’s priority will center on injecting “increased rigor” into the organization. Her mandate includes strengthening R&D productivity, overhauling governance structures, and accelerating innovation capacity to reignite the company’s flagging transformation efforts.

The Pressure Points: Dupixent’s Dominance and Vaccine Challenges

Hudson’s tenure, which began in 2019 with an ambitious mandate to revitalize the drug pipeline and boost shareholder value, faced mounting headwinds. The company’s overreliance on Dupixent—its flagship eczema treatment—became increasingly problematic as market conditions shifted.

Q4 2025 results illustrated the dilemma: Dupixent sales surged 32.2% to €4.2 billion, yet this strength masks a fundamental vulnerability. According to CFO François-Xavier Roger, the approaching loss of exclusivity poses an insurmountable challenge. “We believe we will not be able to mitigate the sales impact as exclusivity erodes. The drug is simply too substantial,” Roger stated.

The vaccine segment added another layer of complexity. Q4 vaccine revenues declined 2.5% to €2 billion, with Beyfortus sales dropping 14.9% to €686 million. Polio/Pertussis/Hib (PPH) vaccines fell 9.5% to €551 million, attributable partly to declining birth rates globally, including China. Influenza and COVID-19 vaccines showed resilience with a 31.5% increase to €575 million.

The Pipeline Play: Amlitelimab as a Potential Turnaround Asset

Sanofi’s future hinges significantly on amlitelimab, positioned as a potential successor to Dupixent in treating moderate-to-severe atopic dermatitis in patients 12 years and older. Early data demonstrated a robust evidence profile supporting its clinical potential, offering hope for pipeline diversification.

The leadership shocker serves as a market signal that stakeholders demand tangible results. Garijo’s appointment suggests a strategic pivot toward operational excellence and accelerated innovation timelines. Market reaction was swift—SNY shares dropped 6.25% to $46.17 during premarket trading, reflecting investor uncertainty about the transition. The coming months will determine whether the new leadership can successfully position Sanofi beyond its Dupixent dependency and rebuild investor confidence through a revitalized drug development strategy.